Accelerating drug repurposing for COVID-19 treatment by modeling mechanisms of action using cell image features and machine learning

Machine learning-assisted flexible wearable device for tyrosine detection

Early diagnosis of pathological markers can significantly shorten the rate of viral transmission, reduce the probability of infection, and improve the cure rate of diseases. Therefore, analytical techniques for identifying pathological markers and environmental toxicants have received considerable attention from researchers worldwide. However, the most popular techniques used in clinical settings involve expensive precision instruments and complex detection processes. Thus, a simpler, more efficient, rapid, and intelligent means of analysis must be urgently developed. Electrochemical biosensors have the advantages of simple processing, low cost, low sample preparation requirements, rapid analysis, easy miniaturization, and integration. Thus, they have become popular in extensive research. Machine learning is widely used in material-assisted synthesis, sensor design, and other fields owing to its powerful data analysis and simulation learning capabilities. In this study, a machine learning-assisted carbon black-graphene oxide conjugate polymer (CB-GO/CP) electrode, in conjunction with a flexible wearable device, is proposed for the smart portable detection of tyrosine (Tyr). Input feature value data are obtained for the artificial neural network (ANN) and support vector machines (SVM) model learning via multiple data collections in artificial urine and by recording the pH and temperature values. The results reveal that a machine-learning model that integrates multiple external factors is more accurate for the prediction of Tyr concentration.

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

COVID-19 caused by SARS-CoV-2 has raised a health crisis worldwide. The high morbidity and mortality associated with COVID-19 and the lack of effective drugs or vaccines for SARS-CoV-2 emphasize the urgent need for standard treatment and prophylaxis of COVID-19. The receptor-binding domain (RBD) of the glycosylated spike protein (S protein) is capable of binding to human angiotensin-converting enzyme 2 (hACE2) and initiating membrane fusion and virus entry. Hence, it is rational to inhibit the RBD activity of the S protein by blocking the RBD interaction with hACE2, which makes the glycosylated S protein a potential target for designing and developing antiviral agents. In this study, the molecular features of the S protein of SARS-CoV-2 are highlighted, such as the structures, functions, and interactions of the S protein and ACE2. Additionally, computational tools developed for the treatment of COVID-19 are provided, for example, algorithms, databases, and relevant programs. Finally, recent advances in the novel development of antivirals against the S protein are summarized, including screening of natural products, drug repurposing and rational design. This study is expected to provide novel insights for the efficient discovery of promising drug candidates against the S protein and contribute to the development of broad-spectrum anti-coronavirus drugs to fight against SARS-CoV-2.

COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments

Background: With the Coronavirus becoming a new reality of our world, global efforts continue to seek answers to many questions regarding the spread, variants, vaccinations, and medications. Particularly, with the emergence of several strains (e.g., Delta, Omicron), vaccines will need further development to offer complete protection against the new variants. It is critical to identify antiviral treatments while the development of vaccines continues. In this regard, the repurposing of already FDA-approved drugs remains a major effort. In this paper, we investigate the hypothesis that a combination of FDA-approved drugs may be considered as a candidate for COVID-19 treatment if (1) there exists an evidence in the COVID-19 biomedical literature that suggests such a combination, and (2) there is match in the clinical trials space that validates this drug combination. Methods: We present a computational framework that is designed for detecting drug combinations, using the following components (a) a Text-mining module: to extract drug names from the abstract section of the biomedical publications and the intervention/treatment sections of clinical trial records. (b) a network model constructed from the drug names and their associations, (c) a clique similarity algorithm to identify candidate drug treatments. Result and Conclusions: Our framework has identified treatments in the form of two, three, or four drug combinations (e.g., hydroxychloroquine, doxycycline, and azithromycin). The identifications of the various treatment candidates provided sufficient evidence that supports the trustworthiness of our hypothesis.